Cholic Acid
( DrugBank: Cholic Acid / KEGG DRUG: Cholic acid )
4 diseases
| ID | Disease name (Link within this page) | Number of trials | 
|---|---|---|
| 20 | Adrenoleukodystrophy | 2 | 
| 234 | Peroxisomal disease (except Adrenoleukodystrophy) | 3 | 
| ID | Disease name (Link within this page) | Number of trials | 
|---|---|---|
| 265 | Lipodystrophy | 1 | 
| 310 | Congenital anomalies syndrome | 1 | 
20. Adrenoleukodystrophy
Clinical trials : 61 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
234. Peroxisomal disease (except Adrenoleukodystrophy)
Clinical trials : 39 / Drugs : 35 - (DrugBank : 12) / Drug target genes : 13 - Drug target pathways : 45
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
265. Lipodystrophy
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|
310. Congenital anomalies syndrome
Clinical trials : 11 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 3 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|